- Home
- UAMY vs LRMR Comparison
UAMY vs LRMR Comparison
Compare UAMY & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAMY
- LRMR
- Stock Information
- Founded
- UAMY 1968
- LRMR N/A
- Country
- UAMY United States
- LRMR United States
- Employees
- UAMY N/A
- LRMR N/A
- Industry
- UAMY Metal Fabrications
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- UAMY Industrials
- LRMR Health Care
- Exchange
- UAMY Nasdaq
- LRMR Nasdaq
- Market Cap
- UAMY 316.8M
- LRMR 360.3M
- IPO Year
- UAMY N/A
- LRMR N/A
- Fundamental
- Price
- UAMY $8.33
- LRMR $4.30
- Analyst Decision
- UAMY Strong Buy
- LRMR Strong Buy
- Analyst Count
- UAMY 6
- LRMR 7
- Target Price
- UAMY $4.40
- LRMR $16.71
- AVG Volume (30 Days)
- UAMY 24.6M
- LRMR 2.5M
- Earning Date
- UAMY 11-13-2025
- LRMR 11-14-2025
- Dividend Yield
- UAMY N/A
- LRMR N/A
- EPS Growth
- UAMY N/A
- LRMR N/A
- EPS
- UAMY N/A
- LRMR N/A
- Revenue
- UAMY $25,728,046.00
- LRMR N/A
- Revenue This Year
- UAMY $208.54
- LRMR N/A
- Revenue Next Year
- UAMY $114.52
- LRMR N/A
- P/E Ratio
- UAMY N/A
- LRMR N/A
- Revenue Growth
- UAMY 134.91
- LRMR N/A
- 52 Week Low
- UAMY $0.49
- LRMR $1.61
- 52 Week High
- UAMY $19.71
- LRMR $9.50
- Technical
- Relative Strength Index (RSI)
- UAMY 43.68
- LRMR 51.07
- Support Level
- UAMY $8.15
- LRMR $3.87
- Resistance Level
- UAMY $13.71
- LRMR $4.50
- Average True Range (ATR)
- UAMY 2.04
- LRMR 0.28
- MACD
- UAMY -0.77
- LRMR -0.01
- Stochastic Oscillator
- UAMY 1.56
- LRMR 65.41
About UAMY United States Antimony Corporation
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.